BlogHeader.png

Jessica LaBombard

Recent Posts by Jessica LaBombard:

Alcami Attending and Presenting at the 59th Annual Land O' Lakes Pharmaceutical Analysis Conference

Alcami will be attending the 59th Annual Land O' Lakes Pharmaceutical Analysis Conference August 12 - 15, 2019 in Madison, WI. Be sure to stop by our booth and connect with our team to learn more about Alcami.

Alcami will also be presenting on Wednesday, August 14, 2019 at 12:00 pm. The presentation is titled: Applying the Regulatory Framework for Extractables and Leachables in the Laboratory. 

Topics: Events

St. Louis Relocation Newsletter

Wilmington, NC – July 25, 2016 – We are pleased to announce the opening of a new world-class laboratory facility in St. Louis. The current site for laboratory operations will be transitioning to a new building located in the Cortex Innovation Community at 4320 Forest Park Ave., Suite 201, St. Louis, MO 63108. 

In order to keep our clients and potential customers updated on the development of the St. Louis relocation, we have created a quarterly newsletter that includes an overview of the relocation, design details, a milestone schedule, growth plan, and more. You can view the newsletter here

Topics: Company News

St. Louis Relocation Regulatory Change Notification

Wilmington, NC – July 25, 2016 – In February, 2016, Alcami, formerly AAIPharma Services Corp./ Cambridge Major Laboratories, announced planned investment of at least $10.7 Million to relocate its St. Louis, MO analytical testing facility to the Cortex Innovation Center.

Following the announcement, a formal Regulatory Change Notification Letter was sent to individuals who work, or have worked, with the Alcami St. Louis site. 

You can read the full Regulatory Change Notification Letter here to learn more about the relocation. 

Topics: Company News

Quality and Regulatory Affairs Notification Letter

By now you should have been notified about our organizations next important step in the transition of joining AAIPharma Services Corp., a leading provider of drug product, development services and analytical testing, with Cambridge Major Laboratories, Inc., a world-class API drug developer and manufacturer. Effective March 16, 2016, our company will officially operate under the name Alcami [al-kuh-mee]. 

The previous name of our business units have been changed with state and local governments, in the D&B database, and with the FDA.  All of our sites within our organization are doing business as (dba) Alcami Corporation.  Following is a table that outlines how each site name / address / FEI / DUNS is identified with the FDA.